Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP-101 in Sporadic or SOD1-Associated ALS
NCT05039099Phase 2Completed
- Sponsor
- AL-S Pharma AG
- Start
- Sep 2021
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of AP-101 in amyotrophic lateral sclerosis (ALS), sponsored by AL-S Pharma AG. Started Sep 2021; status: completed.
02
Drugs
AP-101
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05039099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05039099.